Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060367 | 0.89 | RXFP1 (0.44) | BRD4RXFP1MAPTALDH1A1GRM2 | |
| SCHEMBL3060244 | 0.84 | BRD4 (0.40) | BRD4RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL3059704 | 0.84 | TP53 (0.42) | BRD4RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL3057488 | 0.81 | PDE4B (0.45) | BRD4KMT2AMAPTALDH1A1GRM2 | |
| SCHEMBL3059869 | 0.81 | CYP11B1 (0.41) | BRD4RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL3411110 | 0.81 | BRD4 (0.39) | BRD4RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL3060227 | 0.79 | MAPT (0.41) | RXFP1KMT2AMAPTALDH1A1 | |
| SCHEMBL3062901 | 0.78 | TP53 (0.42) | KCNH2BRD4RAB9AKMT2AMAPT | |
| SCHEMBL3065208 | 0.78 | TSHR (0.45) | BRD4RAB9AKMT2AMAPTALDH1A1 | |
| SCHEMBL3059306 | 0.78 | ALDH1A1 (0.45) | BRD4RAB9AKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | KCNH2 552/4885MDM2 3914/4885BRD4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.